Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 6, 2026

Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

Advances in flavivirus vaccine development.

Beth-Ann G Coller1, David E Clements, Timothy Martyak

  • 1Hawaii Biotech Inc, 99-193 Aiea Heights Drive, Suite 200, Aiea, HI 96701, USA. bcoller@hibiotech.com

Idrugs : the Investigational Drugs Journal
|December 15, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase 1, Open Label, Safety Study of HBV-002 (West Nile Recombinant Subunit Vaccine) in Healthy Adults.

The American journal of tropical medicine and hygiene·2026
Same author

Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine.

Nature medicine·2026
Same author

Summary of human West Nile virus vaccine meeting, 2024: Investigating barriers to development.

Vaccine·2025
Same author

Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model.

Viruses·2025
Same author

rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model.

Viruses·2025
Same author

Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil.

The Lancet. Infectious diseases·2024

Developing new vaccines is crucial for combating flaviviruses, which cause millions of infections annually. Current research focuses on creating safe and effective vaccines for diseases like dengue and yellow fever, as antiviral therapies are unavailable.

Area of Science:

  • Virology
  • Immunology
  • Public Health

Background:

  • Flaviviruses cause millions of infections globally, with significant disease burden from insect-vectored types like dengue and yellow fever.
  • No specific antiviral treatments exist for insect-vectored flavivirus infections, necessitating a focus on preventative measures.
  • Vaccination and vector control are primary strategies for managing flavivirus outbreaks, with vaccines offering a sustainable and cost-effective approach.

Purpose of the Study:

  • To review the current landscape of vaccine development for medically significant flaviviruses.
  • To highlight successes, challenges, and future directions in flavivirus vaccine research.
  • To explore novel vaccine approaches for flaviviruses lacking approved vaccines.

Main Methods:

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Influenza A Virus Studies in a Mouse Model of Infection
10:44

Influenza A Virus Studies in a Mouse Model of Infection

Published on: September 7, 2017

Related Experiment Videos

Last Updated: Jun 6, 2026

Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Influenza A Virus Studies in a Mouse Model of Infection
10:44

Influenza A Virus Studies in a Mouse Model of Infection

Published on: September 7, 2017

  • Comprehensive review of existing literature on flavivirus vaccines.
  • Analysis of vaccine development pipelines and technological advancements.
  • Examination of challenges and successes in clinical and pre-clinical studies.

    • Main Results:

    • The flavivirus vaccine field is dynamic, with ongoing development of improved and novel vaccines.
    • Advances in science and technology are addressing long-standing challenges in vaccine development.
    • Existing vaccines and new candidates show promise for controlling diseases like yellow fever, Japanese encephalitis, and dengue.

    Conclusions:

    • Vaccines represent a critical and increasingly viable strategy for controlling flavivirus infections.
    • Continued innovation in vaccine technology is expected to yield new, safe, and effective vaccines against major flaviviruses.
    • The development of novel vaccines is essential for targets currently lacking approved preventative measures.